Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma.

Sauer, Sandra; Kriegsmann, Katharina; Nientiedt, Cathleen; Schmitt, Anita; Müller-Tidow, Carsten; Raab, Marc-Steffen; Kauer, Joseph

Sauer, Sandra; Kriegsmann, Katharina; Nientiedt, Cathleen; Schmitt, Anita; Müller-Tidow, Carsten; Raab, Marc-Steffen; Kauer, Joseph.

Afiliação

Sauer S; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Kriegsmann K; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Nientiedt C; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Schmitt A; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Müller-Tidow C; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.
Raab MS; National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Kauer J; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.

Transfus Med Hemother ; 50(5): 371-381, 2023 Oct.

Article em En | MEDLINE | ID: mdl-37936633